# Index

*Note:* Page numbers of article titles are in **boldface** type.


ACROMEGALY, 169
  the sella in, 56-63
Addison's disease—
  ACTH secretion in, 145-146
  pathology of the pituitary associated with, 31-32
Adenoma, chromophobe of the pituitary, 39-43
  acromegaly due to, 43-45
  aetiology of, 47-48
  Cushing's disease due to, 45-46
  pathology of, 40-43
  pituitary apoplexy and, 47
  prolactin-secreting, 46-47
  the sella in, 64
Adrenocorticotrophin (ACTH), **137-146**
  assessment of secretion of, 141-143
    basal secretion, 141-142
    dynamic tests for, 143
  biochemical nature of, 137
  biological actions of, 137-138
  cells, binding of human immunoglobulin to, 38
  effects of somatostatin on, 185
  pathophysiology of secretion of, 143-146
    ectopic ACTH syndrome, 145
    in Cushing's disease, 144-145
    in diagnosis of Cushing's syndrome, 143-144
    in Nelson's syndrome, 144-145
    insufficiency, 145-146
  physiological control of, 138-141
    circadian rhythm of, 139
    feedback mechanisms, 140-141
    stress control mechanism, 141
  placental, 151
  related fetal peptides, 149-151
Amenorrhoea, functional endocrine, diagnosis of, 110-111
Androgens, effects of on gonadotrophin secretion, 105
Angiography, 68-70
Anorexia nervosa, 168, 173-176
Antidiuretic hormone, *see* Vasopressin
Apoplexy, pituitary, 47
Azoospermia, 168, 170

BROMOCRIPTINE, in treatment of hyperprolactinaemic hypogonadism, 210-214
  clinical responses to, 211-212
  dose regimen for, 210-211
  pregnancy and, 212-213
  tumour growth and, 213-214

CIRCADIAN rhythm, of ACTH, 139
Craniopharyngioma, 74-75, 168, 169
Cushing's disease, 45-46
  ACTH levels in, 144-145
  the sella in, 63-64
Cushing's syndrome—
  ACTH secretion in diagnosis of, 143-144
  pathology of the pituitary associated with, 32-33

DIABETES—
  insipidus, 237-238
    cranial, 238-239
    nephrogenic, 239
    nicotine-stimulated neurophysin and, 268
    treatment of, 242
  mellitus, effects of somatostatin on, 187
Dopamine, agonists of, to lower prolactin levels, 210-214

ECTOPIC ACTH syndrome, 145
Empty sella syndrome, 39, 70-74
Endorphins, 151-152
Euthyroid subjects, the TRH test in, 89-92

FOLLICLE-STIMULATING hormone (FSH) (*see also* Gonadotrophins)—
  basal levels of, correlation of with stage of spermatogenesis, 106
  regulation of secretion of by inhibin, 107
Follicle-stimulating hormone releasing hormone, *see* Gonadotrophin releasing hormone

GASTRIC acid secretion, effects of somatostatin on, 189-191
Gastric motility, effects of somatostatin on, 191
Gastrin, effects of somatostatin on, 188-189
Glioma, in the optic tract, 75
Glucagon, effects of somatostatin on, 185-186
Glucagonoma, effects of somatostatin on, 187
Glucose, blood, effects of somatostatin on, 186-187
Gonadotrophins—
  assay of, clinical usefulness of, 109-111
  effects of somatostatin on, 185
  pituitary, **101-116**
  secretion of—
    during infancy, 101
    during puberty, 102-103
    during the menstrual cycle, 103-104, 107-108
    in relation to the menopause, 104, 109
    in the adult male, 103
    in the ageing male, 104
    regulation of in males, 105-107
    regulation of in women, 107-109
Gonadotrophin-releasing hormone (Gn-RH)—
  analogues of, 176
  assays of, 176-177
  clinical applications of, **167-179**
  hypothalamic localization of, 157-158
  side effects of, 176
  test, 167-168
    effects of therapy on in males, 171-172
  therapy—
    in adult males, 169-171
    in prepubertal females, 172
    in prepubertal males, 168-169
    ovulation induction by, 173-176
Granuloma, giant cell, 35
Growth—
  genetic regulation of, 117-118
  hormonal determinants of, 119-131
    peptide growth factors, 127-128
    peptide hormones, 119-120
    somatomedins, 120-127
    steroid hormones, 129-131
    thyroid hormones, 128-129
  hormonal regulation of, **117-135**
  hormone (GH)—
    effects of somatostatin on, 182-184
    regulation of growth by, 119-120
    release inhibiting hormone (GH-RIH), *see* Somatostatin
  non-hormonal determinants of, 118-119

HAEMOCHROMATOSIS of the pituitary, 38-39
Hurler's disease, 39
Hyperprolactinaemia, 206-216
  causes of, 207-208
  dopamine agonists in treatment of, 210-214
  in the male, 208-209
  mechanism of hypogonadism, 214-216
  menstrual abnormalities associated with, 208
  pituitary tumours and, 209-210
  the sella in patients with, 65-67
Hyperthyroidism, 86-87
  pathology of the pituitary associated with, 31
  suspected, the TRH test in, 93
Hypogonadism, hyperprolactinaemia as a cause of, 214-216
  treatment of, 210-214
Hypogonadotrophic hypogonadism, diagnosis of, 110
Hypophysectomy, changes in the hypothalamus associated with, 13
Hypophysitis—
  autoimmune, 38
  lymphocytic, 35
Hypothalamo-gonadal disorders, clinical usefulness of gonadotrophin assays in, 109-111
Hypothalmo—pituitary—thyroid axis—
  clinical disorders affecting, 86-88
  preoperative evaluation of, 95-96
Hypothalamus—
  anatomy of, 3-7
  disorders of, 88
    the TRH test and, 94-96
  hormones of—
    identification of, 155-161
    localization of, 155-161
  location of control centres in, **155-165**
  nature of regulatory hormones from, **155-165**
  pathology of, **3-19**
    changes associated with hypophysectomy, 13
    compression of, 14-16
    congenital malformations of, 7
    damage caused by irradiation of, 13-14
    degenerative conditions of, 11
    inflammatory conditions of, 7-9
    invasive tumours of, 16-17
    porphyria, 12
    traumatic lesions of, 9-11
    vascular lesions of, 9
    Wernicke's syndrome, 12-13
Hypothyroidism, 87-88
  suspected, the TRH test in, 93-94

IMMUNOGLOBULINS, binding of to ACTH cells, 38
Infancy, gonadotrophin secretion during, 101
Inflammation, of the pituitary, 34-38
  autoimmune hypophysitis, 38
  giant cell granuloma and, 35
  local sarcoidosis and, 34

lymphocytic hypophysitis, 35
purulent, 34
Inhibin, regulation of FSH secretion by, 107
Insulin—
effects of somatostatin on, 185-186
regulation of growth by, 119-120
Insulinoma, effects of somatostatin on, 187
Internal carotid artery, aneurysm of, 75
Irradiation, damage to the hypothalamus caused by, 13-14
Ischaemia, of the pituitary—
focal, 33
massive, 33-34
stalk section and, 34
Isolated gonadotrophin deficiency, 167, 169
Isolated GH deficiency, 168

KIDNEY, effects of somatostatin on, 192

LACTATION, pathology of the pituitary during, 30
Leukaemia, 77-78
Lipotrophin, **137-154**
biochemical nature of, 146-147
biological actions of, 147
physiology of, 147-149
related fetal peptides, 149-150
Luteinizing hormone (LH) (*see also* Gonadotrophins), spermatogenesis and, 106-107
Luteinizing hormone releasing hormone, *see* Gonadotrophin releasing hormone

MALE—
gonadotrophin secretion in, 103, 104
regulation of gonadotrophin secretion in, 105-107
Melanocyte stimulating hormone (MSH), **137-154**
biochemical nature of, 146-147
biological actions of, 147
physiology of, 147-149
regulation of secretion of, 160
Menopause—
gonadotrophin levels associated with, effects of steroids on, 109
gonadotrophin secretion in relation to, 104
Menstrual cycle—
abnormalities of associated with hyperprolactinaemia, 208
gonadotrophin secretion during, 103-104
Myxoedema, pathology of pituitary associated with, 30-31

NELSON'S syndrome, ACTH secretion in, 144-145

Neurophysin, **261-275**
nicotine-stimulated, 264-269
in diabetes insipidus, 268
in SIADH, 268-269
normal physiological response of, 264-268
oestrogen-stimulated, 269-271
in pathological conditions of the neurohypophysis, 270-271
oxytocin events and, 270
related research areas, 272-273
Nicotine-stimulated neurophysin, 264-269

OESTROGENS—
effects of in postmenopausal women, 109
effects of on gonadotrophin secretion, 105
in regulation of gonadotrophin secretion in eugonadal women, 107-108
with progesterone, in regulation of gonadotrophin secretion, 108
Oestrogen-stimulated neurophysin, 269-271
Oligospermia, 168, 170
Oxytocin, **223-259**
assay methods for, 228-229
biosynthesis of, 225-226
control mechanisms of, 245-229
drug interactions on, 248
hypothalamic localization of, 156
metabolism of, 226-228
oestrogen-stimulated neurophysin and, 270
pathophysiology of, 248
physiological roles of, 246-247
plasma levels of, 247-248

PANCREAS—
endocrine, effects of somatostatin on, 185-188
exocrine, action of somatostatin on, 191-192
Pepsin secretion, effects of somatostatin on, 189-191
Pinealoma, 75
Pituitary—
anatomical relations of, 21
blood supply to, 22-23
cytology of, 23-27
disorders of, 88
the TRH test and, 94-96
effects of somatostatin on, 182-185
histology of, 23-27
histopathology of, **21-52**
—hypothalamic disease, radiological aspects of, **53-81**
inflammation of, 34-38
ischaemia of, 33-34
macroscopic characteristics of, 21
necrosis of, 33
pathology of, 30-33
Addison's disease and, 31-32
Cushing's syndrome and, 32-33

during lactation, 30
during pregnancy, 30
empty sella syndrome, 39
haemochromatosis, 38-39
Hurler's disease, 39
hyperthyroidism and, 31
inflammation of, 34-38
ischaemia of, 33-34
myxoedema and, 30-31
necrosis of, 33
neoplasma of, 39-48
pharyngeal, 30
terminology of, 22
ultrastructure of, 27-30
Pneumoencephalography, 67-68
Porphyria, pathology of the hypothalamus and, 12
Pregnancy—
effect of bromocriptine on, 212-213, 214
pathology of the pituitary during, 30
Prolactin, **201-222**
cells, antibodies to, 35-37
clinical significance of, 206
effects of somatostatin on, 185
normal secretion of, 201-206
mechanisms of control of, 202-206
release inhibiting factor (PIF), 203-205
releasing factor (PRF), 205
secreting adenomas, 46-47
Progesterone, regulation of gonadotrophin secretion by, 108
Progestogens, effects of in postmenopausal women, 109
Puberty—
delayed, 168
diagnosis of, 110
gonadotrophin secretion during, 102-103
in females, 172
in males, 168-169

RADIOLOGY, pituitary, hypothalamic disease and, **53-81**

SALIVARY glands, effects of somatostatin on, 192
Sarcoidosis, 34, 77
Sella turcica—
categories of, 55-56
criteria of abnormalities of, 54-55
in disease, 56-67
acromegaly, 56-63
chromophobe adenomas, 64
Cushing's disease, 63-64
hyperprolactinaemia, 65-67
lesions around, affecting hypothalamic—pituitary function, 74-78
normal, 54
spread of pituitary tumours beyond, 67-74
tomography of, 55
Serotonin, prolactin secretion and, 205-206
Skull, tumours affecting the base of, 75
Somatomedins, 120-127
assay of, 124-125
in vivo effects of, 127
nutritional modification of release of, 125-127
regulation of growth by, **117-135**
source of, 125-127
structure of, 121-124
Somatostatin, **181-200**
analogues of, 194-195
duration of activity of, 182
effects of, 182-194
on the endocrine pancreas, 185-188
on the exocrine pancreas, 191-192
on the kidney, 192
on the pituitary, 182-185
on the salivary glands, 192
on the stomach, 188-191
on the thyroid, 192-193
toxicity of, 193-194
hypothalamic localization of, 158-160
localization of, 182
mechanism of action of, 194
specificity of, 181
Spermatogenesis, relationship of to gonadotrophin secretion, 105-107
FSH, 106
LH, 106-107
Steroid hormones, regulation of growth by, 129-131
Stomach, action of somatostatin on, 188-191
Stress, ACTH control mechanism in, 141
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 243-245
nicotine-stimulated neurophysins in, 268-269

TESTES, involution of with age, 104
Thyroid—
function, control of, 83-86
gland, effects of somatostatin on, 192-193
hormones—
nature of, 83-84
regulation of growth by, 128-129
TRH interactions with, 85-86
Thyrotrophin (TSH), **83-100**
effects of somatostatin on, 184-185
nature of, 83-84
normal secretion of, 84-85
serum levels of, 88-89
serum response of to TRH, 88-96
Thyrotrophin-releasing hormone (TRH), **83-100**
effects of on prolactin secretion, 205

hypothalamic localization of, 156-157
nature of, 83-84
non-TSH responses to, 96
test, 88-96
hypothalamic disease and, 94-96
in euthyroid subjects, 89-92
pituitary disease and, 94-96
suspected hyperthyroidism and, 93
suspected hypothyroidism and, 93-94
therapeutic uses of, 96
thyroid hormone interactions with, 85-86
Thyrotrophin-secreting adenomas, 47
Tomography—
computerized axial, 70
of the sella, 55
Tuberculosis, 76-77

VASOPRESSIN, **223-259**
analogues to, 242
assay methods for, 228-229
biosynthesis of, 225-226
control mechanisms for, 229-230
drug interactions on, 235-237
hypothalamic localization of, 156
metabolism of, 226-228
pathophysiology of, 237-245
cranial diabetes insipidus, 237-238
diabetes insipidus, 237-238
function tests, 239-242
inappropriate secretion of ADH, 243-245
physiological role of, 230-233
plasma levels of, 233-235
Ventricle, third, dilatation of, 78

WATER deprivation tests, 240-242
Wernicke's syndrome, 12-13

IM

# Index

*Note:* Page numbers of article titles are in **boldface** type.


ADDISON'S disease, brittle diabetes and, 409-410
Alkali, in the treatment of diabetic coma, 442-444
Autoimmune diabetes mellitus, 305-316
  antipancreatic humoral, 312-314
  cell-mediated, 310-312
    antipancreatic, 310-312
    late diabetic complications and, 312
  human pathology of, 305-310
    association of juvenile-onset diabetes with autoimmune endocrinopathies, 308-310
    beta-cell destruction in, 305-307
    beta-cell regeneration in, 307-308
    insulitis, 307
    viral role in, 308
  islet-cell antibodies in, 314-316

BETA-CELLS, in the pathology of autoimmune diabetes mellitus, 305-307, 307-308
Biguanides, in the management of mature-onset diabetes, 503-504
Brittle diabetes, 403-419
  aetiology of, 405-414
    emotional causes, 411-414
    excessive insulin dosage, 406-408
    factors affecting insulin action, 410-411
    intercurrent illnesses, 408-410
    simple errors of management, 405-406
  physiological basis of, 404-405
  treatment of, 414-416
    dietary, 415
    emotional aspects of, 416
    insulin, 415-416
    physical examination, 414-415

CARDIAC denervation, in autonomic neuropathy, 377-378
Cardiomyopathy, in diabetes, **377-388,** 385-386
Cardiorespiratory arrest, in autonomic neuropathy, 382-383
Cerebral oedema, during treatment of ketoacidosis, 444-446
Children—
  control of diabetes in, 512-513
  low-dose insulin therapy in, 439
Cigarette smoking, coronary heart disease in the diabetic and, 394-395
Coma, diabetic, **421-455**
  definition of, 421-422
  management of, a guide to, 447-448
  mortality from, 422-423
  pathogenesis of, 423-428
    biochemical genesis of, 423-426
    role of hormones in, 426-428
  symptoms of, 429-431
    gastrointestinal, 430-431
    hypothermia, 431
    in the conscious state, 429-430
  therapy, complications during, 444-447
    cerebral oedema, 444-446
    thromboses, 446-447
  treatment of, 431-444
    alkali, 442-444
    artificial pancreas in, 472
    fluid replacement, 433
    insulin, 433-440, 491-493
      resistance to, 440-441
    potassium, 441-442
Conjugal diabetes, 287-288
Contraception, the diabetic patient and, 514
Coronary heart disease in the diabetic, **389-402**
  morbidity statistics, 392
  mortality statistics, 389-392
    age correlation with, 391-392
  pathology of, 389
  risk factors, 392-396
    cigarette smoking, 394-395
    hypertension, 392-393
    obesity, 395
    plasma lipids, 393-394
  treatment and, 396-399

DIABETES mellitus—
  autoimmune, 305-316
    antipancreatic humoral, 312-314
    cell-mediated, 310-312
    human pathology of, 305-310
    islet-cell antibodies in, 314-316

Diabetes mellitus (*continued*).
autoimmunity in, **305-332**
brittle, **403-419**
aetiology of, 405-414
physiological basis of, 404-405
treatment of, 414-416
conjugal, 287-288
genetics of, **285-303**
classical studies on, 285-287
experimental studies on, 298
genetic counselling, 298-299
inheritance of, 300-301
recessively-inherited syndromes, 297
studies of in twins, 288-291
glucagon and, **333-344**
effect of control of diabetes on, 336-337
molecular pattern of, 336
plasma levels of, 333-335
studies of in experimentally diabetic animals, 335
studies of in spontaneously diabetic animals, 334-335
haemoglobin components in, 295
hyperglucagonaemia, mechanism of in, 338-339
immunity in, **305-332**
inheritance of, 300-301
HL-A antigens and, 293-294
juvenile-onset (JOD), 295
management of, **499-517**
juvenile-onset, 505-510
mature-onset, 500-505
organization of supervision of, 510-516
maturity-onset (MOD), 295, 296-297
non-genetic causes of, 291-293
the heart in, **377-388**
disease of, **389-402**
types of, 295
Diabetic coma, *see* Coma, diabetic
Diabetic complications—
autonomic neuropathy, **377-388**
cardiomyopathy, **377-388**
coma, **421-455**
genetics of, 299-300
retinopathy, **343-375**

EXERCISE, metabolic response to, 470-471

FEET, care of in elderly diabetic patients, 515-516

GASTROINTESTINAL symptoms, of diabetic coma, 430-431
General practitioner, role of in organizing diabetic supervision, 510-512
Genetic counselling, 298-299

Glucagon—
contribution of to the diabetic state, 339-340
diabetes and, **333-344**
molecular pattern of in diabetes, 336
origin of in hyperglucagonaemia, 336-337
plasma levels of, 333-335
effects of control of diabetes on, 337-338
in experimentally diabetic animals, 335
in spontaneously diabetic animals, 334-335
Glucose analysis, continuous, 461-463
blood sampling for, 459-460
computer algorithms for, 463-465
Glucose homeostasis, restoration of by artificial pancreas, 467
Growth hormone (GH), aetiology of diabetic retinopathy and, 370-371

HAEMOGLOBIN, components of in diabetes, 295
Heart, in diabetes, **377-388**
disease of, **388-402**
rate of in, 380-381
HLA antigens—
inheritance of diabetes and, 293-294
juvenile-onset diabetes and, 316-318
Hormones, role of in diabetic coma, 426-428
Hyperglucagonaemia—
mechanism of in diabetes, 338-339
origin of glucagon in, 336-337
Hyperglycaemia, diabetic coma and, 425-426
Hypertension, coronary heart disease in the diabetic and, 392-393
Hypopituitarism, brittle diabetes and, 409-410
Hypothermia, diabetic coma and, 431

IMMUNE function, host defence and, 326-327
Insulin—
allergic reaction to, 324
antagonism of as cause of diabetes, 288
antibodies to, avoidance of formation of, 326
cardiovascular effects of, 381-382
control of diabetes and, 325
deficiency of, diabetic coma and, 426-428
development of late diabetic complications and, 326
excessive dosage in aetiology of brittle diabetes, 406-408
factors affecting dynamics of action of, 410-411
highly-purified, 490-491
immunogenicity of preparations of, 319-326
clinical significance of, 323-326
immunization measurement, 321
immunization procedure, 319-321

Insulin (*continued*).
importance of form of presentation of immunogen, 321-323
recipient reaction, 323
in management of juvenile-onset diabetes, 507-509
in management of mature-onset diabetes, 504
in treatment of brittle diabetes, 415-416
in treatment of diabetic coma, 433-441, 491-493
aims and dangers of, 434-435
continued treatment, 439
intermittent intravenous regimens, 438
low-dose infusion of, 436-438
low-dose intermittent intramuscular injection of, 438-439
low-dose therapy in children, 439
metabolism of, 435-436
resistance to, 440-441
in treatment of mature-onset diabetes, 504
monospecies, 489-490
oral, 495
remission after treatment with, 325
resistance of patient to, 324-325
sensitivity—
conditions decreasing, 408-409
conditions increasing, 409-410
treatment, evolution of, **481-497**
Insulin-dependent diabetes mellitus (IDDM), *see* Juvenile-onset diabetes (JOD)
Insulitis, 307
Islet-cell antibodies (ICAs), 294
in autoimmune diabetes, 314-316

JUVENILE-ONSET diabetes, 295
animal models of, 319
HLA and, 316-318
management of, 505-510
diet in, 505-506
insulin in, 507-509
supervision in, 509-510
urine testing in, 509-510

KETOACIDOSIS, outline guide to management of, 447-448
Ketogenesis, diabetic coma and, 424-425

LIPIDS, plasma, coronary heart disease in the diabetic and, 393-394
Lipolysis, diabetic coma and, 424

MACULOPATHY, 355-357
treatment of, 361-362

Maturity-onset diabetes (MOD), 295
in young people (MODY), 296-297
management of, 500-505
diet in, 500-501
insulin in, 504
tablets for, 501-504, 505
urine testing in, 504-505
weight monitoring in, 505
Menstruation, brittle diabetes and, 408-409
Mild background retinopathy, 354-355
treatment of, 361

NEUROPATHY, autonomic, in diabetes, **377-388**
beat-to-beat variation and, 383-385
cardiac denervation in, 377-378
cardiorespiratory arrests in, 382-383
cardiovascular effects of insulin in, 381-382
heart rate changes on standing in, 380-381
tachycardia in, 378-380
Non-insulin-dependent diabetes mellitus (NIDDM), *see* Maturity-onset diabetes (MOD)

OBESITY, coronary heart disease in the diabetic and, 395
Oral glucose tolerance, restoration of by artificial pancreas, 467-470

PANCREAS, artificial, **457-479**
clinical studies with, 467-474
antidiabetic action of somatostatin, 472-473
glucose homeostasis restoration, 467
metabolic response to exercise, 470-471
oral glucose tolerance restoration, 467-470
treatment of diabetic coma, 472
computer algorithms for the regulation of blood glucose, 463-465
evolution of, 458-459
experimental studies with, 466-467
glucose infusions, 466
insulin administration, 466-467
hormone delivery systems, 465-466
Photocoagulation, in the treatment of diabetic retinopathy, 360-366
Potassium, in treatment of diabetic coma, 441-442
Prediabetes, 297-298
Pregnancy—
insulin treatment of diabetes in, 493
supervision of diabetes in, 513-514
Proliferative retinopathy, 357-360
treatment of, 362-365

RETINOPATHY, diabetic, **345-375**
aetiology of, 366-371
basement membrane changes, 366-367
blood constituent changes, 369-370
blood flow changes, 368-369
capillary pericytic changes, 367
endothelial cell changes, 367-368
growth hormone and, 370-371
revascularization, 370
clinical types of, 354-360
advanced diabetic eye disease, 360
maculopathy, 355-357
mild background retinopathy, 354-355
proliferative retinopathy, 357-360
evolution of, 345-360
lesions and their significance, 345-354
extravascular, 349-354
vascular, 345-349
management of, 514-515
treatment of, 360-366
advanced diabetic eye disease, 365-366
maculopathy, 361-362
mild background retinopathy, 361
proliferative retinopathy, 362-365

SOMATOSTATIN, antidiabetic action of, 472-473
Somogyi effect, 406-408
Sulphonylureas, in management of mature-onset diabetes, 502-503, 504

TACHYCARDIA, in autonomic neuropathy, 378-380
Thromboses, during treatment of diabetic coma, 446-447
Thyrotoxicosis, brittle diabetes and, 408-409
Twins, studies of diabetic occurrence in, 288-291
at King's College Hospital, 289-291

, 361
-365

on of, 472-

of mature-

neuropathy,

of diabetic

d, 408-409
ace in, 288-

-291

MI

# Index

Note: Page numbers of chapter titles are in **boldface** type.


ACETYL choline—
  action of on secretion of catecholamines, 560-561
  effects on chromaffin cells, 567
Adenylate cyclase, 581-585
  cationic requirements of, 583-584
  guanine nucleotides, effects of, 584-585
  regulation of activity of, 582-583
  second messenger concept, 581-582
Adipose tissue, metabolic effects of catecholamines on, 603-604
Adrenal cortex, role of in catecholamine synthesis, 556-557
Adrenal medulla—
  anatomy of, 551-553
  catecholamine release from, **551-576**
  effects on adipose tissue, 603-605
  effects on muscle, 606-607
  effects on the liver, 602-603
Adrenergic blocking agents—
  in the management of hyperthyroidism, 707-713
    clinical use in thyrotoxicosis, 708-710
    clinical uses, 708-713
    physiological effects, 707-708
  in the treatment of phaeochromocytoma, 789-790
Adrenergic mechanisms, in cardiovascular regulation, 634-637
Adrenergic receptors, **577-598**
  alpha, 591-594
    calcium transport and, 593
    cyclic AMP and, 592-593
    cyclic GMP and, 593-594
  beta, 585-590
    binding to, 585-586
    biomembranes and, 587-588
    mobile receptor theory, 588-590
    modulation of, 586-587
  classification of, 577-580
  thyroid hormones and, 705-706
Adrenergic transmitters, false, 535
Amyloid, in neuroendocrine tumours, 731
APUD cell concept, 726-727
Aromatic amino acid decarboxylase, 527
  inhibition of, 529
Autonomic nervous system—
  diseases of, **745-768**
    autonomic neuropathy, 758-759
    diagnosis of, 750-755
    familial dysautonomia, 759-760
    idiopathic orthostatic hypotension, 755-757
    peripheral neuropathy and, 757-758
    Shy Drager syndrome, 755-757
    tumours, 760-763
  neuroanatomy of, 746-750
    central connections, 746-747
    neuroendocrine transducers, 750
    peripheral organization, 747-750

BETA blocking agents (*see also* Adrenergic blocking agents), hypotensive action of, 647-651
Brown fat, 605

CALCITONIN, 679-681
Calcium—
  infusion of in test of neuroendocrine tumour, 725
  role of in catecholamine secretion, 561-563
  transport of, 593
Calorigenic effects of catecholamines, thyroid status and, 704-705
Carcinoid tumours, 736-738
Cardiovascular regulation, adrenergic mechanisms in, 634-637
Cardiovascular system, effects of catecholamines on, 702-704
  direct effects, 703-704
  in thyrotoxic patients, 703
  studies in experimental animals, 702-703
Catecholamines—
  circulating levels of, 540-541, 640-645
  effects of on gastrin release, 673-675
  effects of on glucagon release, 666-673
  effects of on insulin release, 666-673
  effects of on renin release, 658-665
  effects of on thyroid hormones, 677-679, 697-700
  hyperthyroidism and, **697-718**
  hypoglycaemic changes in, 614-617
  inhibition of, 790-791
  intermediary metabolism and, **599-631**
  metabolic effects of, 599-607
    adipose tissue, 603-605
    liver, 601-603
    muscle, 605-607

Catecholamines (*continued*)
metabolism of, **525-549**
biosynthesis of, 526-531, 553-557
catabolism of, 535-540
enzymes involved in, 527-528, 553-556
inhibitors of, 528-530
regulation of, 530-531
regulation of hormone secretion and, **657-695**
release of from the adrenal medulla, **551-576**
role of in integration of endocrine secretion, 682-684
role of in substrate mobilization, 607-623
feeding and, 610-612
in exercise, 619-621
in hypoglycaemia, 612-617
in pathophysiological states, 621-623
in starvation, 607-610
in thermogenesis, 617-619
secretion of, 559-567
action of acetyl choline, 560-561
exocytosis, 563-564, 565-567
role of calcium, 561-563
sensitivity of tissues to, effect of thyroid hormones on, 701-707
storage of, 557-559
uptake of, 537-538, 557
urinary excretion of, 540, 638-640
Cations, requirements of for adenylate cyclase activity, 583-584
Chromaffin cells, effects of acetyl choline on, 567
Cold exposure, 617-619
Co-operativity, 588-590
Cyclic AMP, 592-593
Cyclic GMP, 593-594

DESMOPLASIA, tumour-induced, 731
Dopamine-β-hydroxylase, 527
inhibition of, 529
plasma levels of, 541-542, 640
Dopaminergic receptor, 590-591

ERYTHROPOIETIN, 682
Exercise—
glucagon and, 671-672
insulin and, 671-672
metabolic changes in, 619-621
physical conditioning to, 621
renin release and, 664
Exocytosis, catecholamine secretion and, 563-564
mechanisms of, 565-567

FAMILIAL dysautonomia, 759-760

Fasting—
gastrin and, 675
glucagon release and, 670-671
insulin release and, 670-671
Feeding—
gastrin and, 675
glucagon release and, 670-671
insulin release and, 670-671
sympatho-adrenal activity and, 610-612

GANGLIONEUROBLASTOMA, 763
Ganglioneuroma, 763
Gastrin, 673-677
effects of catecholamines on, 673-675
infusions of agonists, 674-675
infusions of antagonists, 674-675
innervation, 673
nerve stimulation and, 674
physiological role of the sympatho-adrenal system in secretion of, 675-677
fasting, 675
feeding, 675
hypoglycaemia, 675-676
pathophysiological states, 676
peptic ulcers, 676-677
Glucagon, 665-673
effects of catecholamines on, 666-670
agonist infusions, 668-669
antagonist infusions, 669-670
innervation, 666
isolated preparation, 666-667
nerve stimulation and, 667-668
physiological role of catecholamines in control of release of, 670-673
exercise, 671-672
fasting, 670-671
feeding, 670-671
glucose tolerance, 670-671
hypoglycaemia, 672
in pathophysiological states, 672-673
stimulation of neuroendocrine tumours by, 725-726
Glucose tolerance—
effects of glucagon on, 670-671
effects of insulin on, 670-671
Guanine nucleotides, effects of on adenylate cyclase activity, 584-585

HORMONE release—
catecholamines and regulation of, **657-695**
role of catecholamines in integration of, 682-684
Hypertension—
neurogenic component in, 637-645
the sympathetic system in, **633-655**
significance of, 645-647

Hyperthyroidism—
catecholamines and, 697-718
management of, 707-713
physiological effects of adrenergic blockade, 707-708
Hypoglycaemia—
catecholamines in the pathophysiology of, 617
gastrin and, 675-676
glucagon and, 672
insulin and, 672
physiological responses to catecholamines and, 614-617
renin release and, 664
sympatho-adrenal response to, 612-614
Hypotension, induction of by beta blockers, 647-651

IDIOPATHIC orthostatic hypotension, 755-757
Insulin, 665-673
effects of catecholamines on, 666-670
agonist infusions, 668-669
antagonist infusions, 669-670
innervation, 666
isolated preparation, 666-667
nerve stimulation and, 667-668
physiological role of catecholamines in control of the release of, 670-673
exercise, 671-672
fasting, 670-671
feeding, 670-671
glucose tolerance, 670-671
hypoglycaemia, 672
in pathophysiological states, 672-673
Intermediary metabolism, catecholamines and, **599-631**

LIPOLYSIS, during starvation, 609-610
Liver—
blood flow, 603
metabolic effects of catecholamines on, 601-602

MUSCLE, metabolic effects of catecholamines on, 605-606

NEURAL crest, as origin of neuroendocrine cells, 731-732
Neuroblastoma, 760-762
Neuroendocrine transducer cells, 750
Neuroendocrine tumours, *see* Tumours, neuroendocrine
Neuropathy—
autonomic, 758-759
peripheral, autonomic failure associated with, 757-758
Norepinephrine (noradrenaline)—
metabolic fate of at sympathetic nerve endings, 538-540
release of from sympathetic nerves, 532-535
control of, 533-534
mechanism of, 532-533
pharmacologically-induced, 535
storage of in sympathetic nerves, 531-532

OAT cell carcinoma, 738-739

PANCREAS, islet cell tumours of, 739
Parathyroid hormone, 681-682
Peptic ulcers, gastrin and, 676-677
Phaeochromocytoma, **769-797**
clinical features of, 770-778
diagnosis of, 776-789
anatomical localization of, 782-784
biochemical tests for, 780-782
localizing tests for, 784-789
pharmacological tests for, 779-780
historical features of, 769-770
therapy for, 789-795
adrenergic blocking drugs, 789-790
anaesthetic considerations, 791-793
catecholamine synthesis inhibition, 790-791
postoperative considerations, 793-795
surgical considerations, 791-793
Phaeochromocytoma—neuroblastoma, 740-741
Phenylethanolamine-N-methyl transferase, 527-528
inhibition of, 529-530
Plasma—
levels of catecholamines in, 540-541, 640-645
levels of dopamine-β-hydroxylase in, 541-542, 640
Pupillary function, pharmacological tests of, 751

RECEPTORS—
adrenergic, **577-598**
alpha, 591-594
beta, 585-590
classification of, 577-580
concepts concerning, 580-581, 581-582
co-operativity between, 588-590
dopaminergic, 590-591
mobility of, 588-590
Renin, 658-665
effect of catecholamines on release of, 659-661

Renin (*continued*)
infusion of agonists, 661
infusion of antagonists, 661
innervation, 659
isolated preparations, 659-660
nerve stimulation and, 660-661
physiological role of catecholamines in control of, 662-665
acute sodium depletion, 662-663
chronic sodium depletion, 662
exercise, 664
hypoglycaemia, 664
in pathophysiological states, 664-665

SECOND messenger concept, 581-582
Shy Drager syndrome, 755-757
Sodium, depletion of, renin release and, 662-663
Starvation—
activity of the sympatho-adrenal system in, 607-608
lipolysis in, 609-610
Sudomotor function, tests of, 754-755
Sympathetic activity, biochemical assessment of, **525-549**
Sympathetic nerves—
effects on adipose tissue, 603-605
effects on muscle, 606-607
effects on the liver, 602-603
effects on the thyroid, 697-699
metabolic fate of norepinephrine in, 538-540
release of norepinephrine from, 532-535
control of, 533-534
mechanism of, 532-533
pharmacologically-induced, 535
storage of norepinephrine in, 531-532
uptake of catecholamines by, 537-538
Sympathetic nervous system—
abnormalities of, biochemical indices of, 542-543
in hypertension, **633-655**
significance of, 645-647
Sympatho-adrenal medullary activity, biochemical assessment of, 540-543
Sympatho-adrenal system, effects of thyroid hormones on, 700-701

THERMOGENESIS, sympatho-adrenal involvement in, 617-619
Thymoma, malignant epithelial, 740
Thyroid, 677-679
effects of catecholamines on, 677-679
infusions and, 678-679
innervation, 677-678
isolated preparations, 678
nerve stimulation and, 678-679
medullary carcinoma of, 733-736
Thyroid hormones—
adrenergic receptors and, 705-706
calorigenesis and, 704-705
effects of catecholamines on, 697-700
biosynthesis, 699
metabolism, 700
release, 699
effects of on sympatho-adrenal system, 700-701
effects of on sensitivity of tissues to catecholamines, 701-707
cardiovascular system, 702-704
Thyrotoxicosis—
adrenergic blocking agents in management of, 708-712
choice of drug, 709-710
in pregnancy, 712
effects of catecholamines in, 703
Tumours, neuroendocrine, **719-744**
amyloid, 731
APUD cell concept, 726-727
carcinoid, 736-738
characteristic secretions of, 721-724
desmoplasia, 731
glandular appearance of, 727-731
islet cell tumours of the pancreas, 739
malignant epithelial thymomas, 740
medullary carcinoma of the thyroid, 733-736
neural crest origin of, 731-732
oat cell carcinoma, 738-739
phaeochromocytoma—neuroblastoma, 740-741
provocative tests of hormone release, 725-726
calcium infusion, 725
glucagon stimulation, 725-726
similarities between, 732-733
Tyrosine hydroxylase, 527
inhibitors of, 528-529

URINE, excretion of catecholamines in, 540, 638-640

VAGAL function, tests of, 753-754
Vasomotor function, tests of, 751-753
cold pressor, 752
drug responses, 753
inspiratory gasp reflex, 753
mental stress, 753
tilt table manoeuvre, 752
valsalva manoeuvre, 751-752
vasodilator response, 753

NDEX

0

a, 700-
echol-

ement

39
, 733-

a, 740-
, 725-

, 540,